Ampullary Neuroendocrine Tumors: Multicenter Experience and Emerging Perspectives on Endoscopic Treatment

Read full text
Authors: Digestive Endoscopy Unit, AOU San Giovanni e Ruggi-Fucito Unit, Salerno, Italy, Federica Fimiano, Lorenzo Dioscoridi, Digestive Endoscopy Unit, ASST Niguarda, Milan, Italy, Marta Stegagnini, Digestive Endoscopy Unit, ASST Niguarda, Milan, Italy, Edoardo Forti, Digestive Endoscopy Unit, ASST Niguarda, Milan, Italy, Francesco Pugliese, Digestive Endoscopy Unit, ASST Niguarda, Milan, Italy, Marcello Cintolo, Digestive Endoscopy Unit, ASST Niguarda, Milan, Italy
+17 more Giulia Bonato, Digestive Endoscopy Unit, ASST Niguarda, Milan, Italy, Marianna Bravo, Digestive Endoscopy Unit, ASST Niguarda, Milan, Italy, Andrea Palermo, Digestive Endoscopy Unit, ASST Niguarda, Milan, Italy, Camilla Gallo, Digestive Endoscopy Unit, ASST Niguarda, Milan, Italy, Ceclia Binda, Claudio Zulli, Digestive Endoscopy Unit, AOU San Giovanni e Ruggi-Fucito Unit, Salerno, Italy, Piera Zaccari, Alberto Mariani, Armando Gabbrielli, Paolo Arcidiacono, Massimiliano Mutignani, Digestive Endoscopy Unit, ASST Niguarda, Milan, Italy
Cited by: 0
References: 25

Abstract

BACKGROUND: Ampullary neuroendocrine tumors (NETs) are extremely rare, representing 0.3%-1% of gastrointestinal NETs and less than 2% of periampullary cancers. Due to their rarity, there is limited data on their natural history, management, and outcomes. Current European Neuroendocrine Tumor Society guidelines (2023) recommend pancreaticoduodenectomy (PD) as the standard treatment. However, this approach is invasive and associated with high morbidity and mortality. Emerging evidence suggests that endoscopic papillectomy (EP) could be a viable alternative in selected cases. This retrospective multicenter study aimed to evaluate the feasibility and outcomes of endoscopic resection for ampullary NETs. METHODS: This retrospective case series included 14 patients who underwent EP for ampullary NETs between 2011 and 2022 across three Italian tertiary centers. Pre-procedural evaluation was performed following European Society of Gastrointestinal Endoscopy guidelines. Endoscopic papillectomy was performed under monitored sedation, using standard snares for en bloc resection. Follow-up endoscopy was conducted at a median of 3 months. Primary outcomes included complete resection (R0) and recurrence rates; secondary outcomes focused on adverse events. RESULTS: Fourteen patients (median age: 62.5 years; 50% male) were included. Median tumor size was 18 mm. In 12 out of 14 cases, ampullary NETs were diagnosed only after endoscopic resection. Post-resection histology identified 8 G1 NETs (Ki-67 1%) and 6 G2 NETs (Ki-67 5%). Complete resection was achieved in 11 cases (78.6%). Among 3 incomplete resections, 2 were managed surgically, while 1 was followed up without recurrence. Residual disease was detected in 3 patients: 2 were managed endoscopically, and 1 required surgery. No recurrences occurred during a median follow-up of 14.5 months. Adverse events occurred in 42.9% of patients, including 5 cases of bleeding and 1 case of mild pancreatitis, all resolved without major sequelae. Median hospital stay was 2.5 days. CONCLUSIONS: Our findings suggest that EP offers a promising alternative to surgery in selected patients with ampullary NETs. Endoscopic resection was associated with high rates of R0 and favorable short-term outcomes, with effective endoscopic management of residual disease and procedure-related adverse events. Consistent post-procedural surveillance remains essential to detect residual or recurrent disease. Larger prospective studies are warranted to refine patient selection criteria, optimize protocols, and establish the long-term efficacy.

Fields of Study & Subjects

Neuroendocrine Tumor Research Advances Gastrointestinal Tumor Research and Treatment Pancreatic and Hepatic Oncology Research

Publication details

Journal / source
Rambam Maimonides Medical Journal
Volume
17
Issue
1
Pages
e0001–e0001
Publication date
28 January 2026
Language
EN